In the final video of this Rapid Reactions series, Beth Sandy, MSN, CRNP, FAPO, discusses data that continue to favor first-line amivantamab plus lazertinib over osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer after a median of 31 months of follow-up.
Beth Sandy, MSN, CRNP, FAPO Thoracic Oncology Nurse Practitioner Abramson Cancer Center, University of Pennsylvania Philadelphia, PA
Sponsored by
To sign up for our newsletter or print publications, please enter your contact information below.
